Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS’ Predictive ...

For India’s new-age startups now navigating public markets, the real test is no longer just growth. It is resilience.

Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilize ...

CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling ...

Objective A panel of antibodies against three antigens, University Hasselt (UH)-rheumatoid arthritis (RA).305, 318 and 329, has been associated with lack of response to first-line therapy in the Care ...

Detailed price information for Day One Biopharmaceuticals Inc (DAWN-Q) from The Globe and Mail including charting and trades.

Researchers at Mass General Brigham have developed a series of artificial intelligence (AI) tools that uses machine learning ...

A simple test that can accurately predict whether an individual will respond to a given medication would benefit all patients, clinicians, and reimbursement authorities, as well as create new drug ...

Zevra Therapeutics (NASDAQ:ZVRA) reported fourth quarter and full-year 2025 results highlighted by growing commercial traction for its Niemann-Pick disease type C (NPC) therapy MIPLYFFA and a shift to ...

By Hugo Francisco de Souza A large NHS screening study shows that artificial intelligence can detect subtle signals in ...

In 2025, we were very pleased to report tremendous progress across all pillars of the company. First of all, in business development, we were delighted with the progress in our collaboration with MSD ...

A research team from the Department of Pharmacology and Pharmacy at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has developed an innovative AI-based cardiovascular risk ...